| Patient | Jacqueline Mary du Pré |
|---|---|
| Date of birth | 1945-01-26 |
| Identifiers | MRN HR-ML039-SYN-TD; SSN (made up) 000-39-7062 |
| Document date | 1973-07-13 |
| Author | Imogen Thackeray-Osei, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Three months on ocrelizumab: re-baseline MRI review. [S]
Ms. du Pré returns three months after her first ocrelizumab infusion, after a re-baseline MRI five days ago. The cystitis four weeks ago cleared with nitrofurantoin, and the tingling that came back with the fever went within two days of it. She has had no new symptoms. Feeling in her fingers is almost normal except after long practice, and she practices three hours a day. She has started swimming twice a week, which helps the fatigue, and rests after lunch. She played a private recital for friends last week. She takes cholecalciferol daily. [S]
| Element | Detail |
|---|---|
| Disease activity | No relapse since starting ocrelizumab; re-baseline MRI with no new or enhancing lesions |
| Intercurrent illness | Cystitis with a pseudo-relapse four weeks ago, resolved |
| Hand function | Practicing three hours a day; private recital last week |
| Fatigue | Better with swimming, pacing and an after-lunch rest |
| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Mild late-afternoon fatigue; no fever |
| Neurological | Positive | Faint tingling in the left fingertips after long practice; no new symptoms |
| Genitourinary | Negative | No urinary symptoms since the cystitis |
| Respiratory | Negative | No cough |
| Integumentary | Negative | No rash |
| Psychiatric | Negative | Mood good; PHQ-9 4; no thoughts of self-harm |
6 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Nitrofurantoin macrocrystals 100 mg oral capsule, one capsule by mouth twice daily with food for 5 days | One capsule twice daily for 5 days | Oral route | 1973-06-15 to 1973-06-19 | completed | S |
| Methylprednisolone 1000 mg injection, 1 g intravenously over one hour once daily for 3 days | 1 g daily for 3 days | Intravenous route | 1973-03-24 to 1973-03-26 | completed | S |
| Cholecalciferol (vitamin D3) 4000 unit (100 microgram) oral capsule, one capsule by mouth daily | One capsule daily | Oral route | 1973-03-23 | active | S |
| Ocrelizumab 30 mg/mL injection: first dose as 300 mg intravenously on day 1 and day 15, then 600 mg intravenously every 6 months, with methylprednisolone 100 mg, an antihistamine and acetaminophen before each infusion | 300 mg on days 1 and 15, then 600 mg every 6 months | Intravenous route | 1973-04-13 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 1973-07-13 | Body height | 173 | cm | S |
| 1973-07-13 | Body weight | 64 | kg | S |
| 1973-07-13 | Body mass index (BMI) [Ratio] | 21.4 | kg/m2 | S |
| 1973-07-13 | Systolic blood pressure | 110 | mm[Hg] | S |
| 1973-07-13 | Diastolic blood pressure | 70 | mm[Hg] | S |
| 1973-07-13 | Heart rate | 70 | /min | S |
| 1973-07-13 | Respiratory rate | 14 | /min | S |
| 1973-07-13 | Body temperature | 36.6 | Cel | S |
| 1973-07-13 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 1973-07-13 | Hemoglobin [Mass/volume] in Blood | 13.5 | g/dL | 12-15.5 g/dL | Normal | S |
| 1973-07-13 | Leukocytes [#/volume] in Blood by Automated count | 6.1 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 1973-07-13 | Lymphocytes [#/volume] in Blood by Automated count | 1.5 | 10*3/uL | 1-4.8 10*3/uL | Normal | S |
| 1973-07-13 | Platelets [#/volume] in Blood by Automated count | 240 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 1973-07-13 | CD19 cells [#/volume] in Blood | 3 | /uL | 100-500 /uL | Low | S |
| 1973-07-13 | IgG [Mass/volume] in Serum or Plasma | 990 | mg/dL | 700-1600 mg/dL | Normal | S |
| 1973-07-13 | 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma | 34 | ng/mL | Below 20 ng/mL deficient; 20 to 29 insufficient | Normal | S |
| 1973-07-13 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 4 | {score} | S | ||
| 1973-07-13 | 9-Hole Pegboard Dexterity Test Time Hand - right [NIH Toolbox] | 19 | s | S | ||
| 1973-07-13 | 9-Hole Pegboard Dexterity Test Time Hand - left [NIH Toolbox] | 20.5 | s | S |
Vital signs recorded on 1973-07-13; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well; weight 64.0 kg; blood pressure 110/70 |
| Neurological | Vibration slightly reduced in the left fingertips only; joint position, strength, reflexes and gait normal; no Lhermitte's sign. Nine-hole peg test 19.0 seconds right, 20.5 seconds left. EDSS 1.0 |
| Psychiatric | Bright, warm and engaged |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Numbness, tingling and loss of position sense in the fingers of both hands for three weeks, worse on the left, with clumsiness that makes her lose her place on the fingerboard, an electric feeling down the spine on bending the neck (Lhermitte's sign), and fatigue; a similar month of tingling in the fingers 18 months ago settled on its own. A lesion of the cervical spinal cord must be found: MRI of the brain and spine with contrast booked this week | resolved | confirmed | R20.2 | S — Synthetic presenting problem anchored to her documented loss of sensation in her fingers and fatigue. Superseded by the diagnosis at the second visit. |
| Relapsing-remitting multiple sclerosis, active: a current relapse (partial cervical myelitis at C3 to C4 with sensory loss and clumsiness of the hands) after an earlier sensory episode; dissemination in space and time on MRI, with an enhancing cord lesion and an enhancing brain lesion; CSF-specific oligoclonal bands; aquaporin-4 antibody negative; meets the 1964 McDonald criteria and the 1971 revision; synthetic modern detail linked to her documented diagnosis | active | confirmed | G35.A | S — Synthetic course, imaging and laboratory detail; linked to her documented diagnosis in October 1973. |
| Vitamin D deficiency: 25-hydroxyvitamin D 16 ng/mL; replacement to correct the deficiency, not as a treatment for multiple sclerosis | active | confirmed | E55.9 | S — Synthetic finding. |
| Acute uncomplicated cystitis (Escherichia coli) seven weeks after the first ocrelizumab course, with a pseudo-relapse: two days of returning tingling in the fingers with a low fever and no new neurological deficit; resolved | resolved | confirmed | N30.00 | S — Synthetic intercurrent infection; not a historical claim. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Imaging | Re-baseline MRI of the brain | Three to six months after starting a disease-modifying therapy, then yearly | Up to date | Five days ago: no new or enlarging T2 lesions, no enhancement |
| Laboratory | Blood count with lymphocytes | Every three to six months on ocrelizumab | Completed today | Hemoglobin 13.5 g/dL, white cells 6.1, lymphocytes 1.5, platelets 240 |
| Laboratory | CD19 B-cell count | When needed to confirm depletion | Completed today | 3 per microliter: depleted, as expected |
| Laboratory | Immunoglobulins (IgG, IgM) | At baseline and before each ocrelizumab dose | Completed today | IgG 990 mg/dL |
| Laboratory | 25-hydroxyvitamin D | About three months after starting replacement | Completed today | 34 ng/mL |
| Laboratory | Hepatitis B surface antibody after vaccination | One to two months after the last dose, for people on immunosuppressive therapy | Deferred | Missed: the antibody check due one to two months after the second hepatitis B dose was not ordered. No harm is expected in the meantime, since she has no hepatitis B exposure; corrective action: added to the blood tests before the next ocrelizumab dose, and post-vaccination serology added to the clinic's B-cell therapy checklist |
| Medication safety | Vaccination | Complete series where possible | Completed today | Recombinant zoster dose 2 today |
| Medication safety | Infections on anti-CD20 therapy | Each review | Completed today | One uncomplicated cystitis, treated; no other infection |
| Examination | Hand function: nine-hole peg test, both hands | At diagnosis, after a relapse, and at each review | Completed today | 19.0 seconds right, 20.5 seconds left |
| Examination | Neurological examination and EDSS | Each review | Completed today | EDSS 1.0 |
| Survey | Mood and anxiety (PHQ-9, GAD-7) | At diagnosis and at each review | Completed today | PHQ-9 4; item 9 scored 0 |
| Self-management | Fatigue: causes and management | Each review | Completed today | Aerobic exercise (swimming), pacing and rest; no medicine needed |
Goal progress:
Immunizations given today: Recombinant zoster vaccine, dose 2 of 2 [S]
Guideline basis: Rae-Grant A, et al. Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis. Neurology 2018;90(17):777-788 (PMID 29686116) (2018); Montalban X, et al. ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis. Mult Scler 2018;24(2):96-120 (PMID 29353550) (2018); Multiple sclerosis in adults: management (NICE guideline NG220) (2022); Wattjes MP, et al. 2021 MAGNIMS-CMSC-NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis. Lancet Neurol 2021;20(8):653-670 (PMID 34139157) (2021); Farez MF, et al. Practice guideline update summary: Vaccine-preventable infections and immunization in multiple sclerosis. Neurology 2019;93(13):584-594 (PMID 31462584) (2019)
Follow-up: Ocrelizumab 600 mg in three months with blood tests beforehand; preventive visit due; call for fever, urinary symptoms or any new neurological symptom. Next scheduled visit 1973-09-14: periodic adult preventive visit on B-cell therapy. [S]